低危前列腺癌:识别、管理与结局
本文为协作综述,检索Medline、Embase和Web of Science数据库,评估低危前列腺癌的预后与治疗选择。前瞻性随机试验未能显示根治性治疗对低危患者癌症特异性生存的影响;主动监测长期可行,但约30%男性在5年内接受治疗;局灶治疗数据尚需长期生存证据,应视为实验性。
要点
- 前瞻性随机试验未显示根治性治疗对低危前列腺癌患者癌症特异性生存有益。
- 主动监测长期可行,但约30%开始主动监测的男性在5年内接受治疗。
- 局灶治疗对长期生存结局的稳健数据仍需,应视为实验性。
核心结论
- 低危前列腺癌发病率近年增加,仅小部分男性进展为临床症状、转移或死亡,前瞻性试验未显示立即根治性治疗的获益。
- 组织生物标志物、磁共振成像和持续监测可能有助于识别携带更具临床显著疾病的低危前列腺癌男性。
研究设计与样本
- 协作综述文章,对Medline、Embase和Web of Science数据库进行文献回顾。
- 检索策略包括前列腺癌、低危、主动监测、局灶治疗、根治性前列腺切除术、观察等待、生物标志物、磁共振成像等术语,单独或组合使用。
主要发现
- 前瞻性随机试验未能显示根治性治疗对低危前列腺癌患者癌症特异性生存的影响。
- 多个系列报告了根治性前列腺切除术中的不良病理结局风险,但这些患者是否有更高前列腺癌死亡风险尚不清楚。
- 长期随访表明主动监测在低危前列腺癌患者中可行,但约30%开始主动监测的男性在5年内接受治疗。
- 关于局灶治疗对长期生存结局影响的稳健数据仍需,因此应视为实验性。
- 磁共振成像和组织生物标志物可能有助于预测初诊低危疾病男性中的临床显著前列腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. OBJECTIVE: In this collaborative review article, we examine recent literature regarding low-risk PCa and the available prognostic and therapeutic options. EVIDENCE ACQUISITION: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms: prostate cancer, low risk, active surveillance, focal therapy, radical prostatectomy, watchful waiting, biomarker, magnetic resonance imaging, alone or in combination. EVIDENCE SYNTHESIS: Prospective randomized trials have failed to show an impact of radical treatments on cancer-specific survival in low-risk PCa patients. Several series have reported the risk of adverse pathologic outcomes at radical prostatectomy. However, it is not clear if these patients are at higher risk of death from PCa. Long-term follow-up indicates the feasibility of active surveillance in low-risk PCa patients, although approximately 30% of men starting active surveillance undergo treatment within 5 yr. Considering focal therapies, robust data investigating its impact on long-term survival outcomes are still required and therefore should be considered experimental. Magnetic resonance imaging and tissue biomarkers may help to predict clinically significant PCa in men initially diagnosed with low-risk disease. CONCLUSIONS: The incidence of low-risk PCa has increased in recent years. Only a small proportion of men with low-risk PCa progress to clinical symptoms, metastases, or death and prospective trials have not shown a benefit for immediate radical treatments. Tissue biomarkers, magnetic resonance imaging, and ongoing surveillance may help to identify those men with low-risk PCa who harbor more clinically significant disease. PATIENT SUMMARY: Low-risk prostate cancer is very common. Active surveillance has excellent long-term results, while randomized trials have failed to show a beneficial impact of immediate radical treatments on survival. Biomarkers and magnetic resonance imaging may help to identify which men may benefit from early treatment.
引用
- Moschini M, Carroll PR, Eggener SE, et al. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017. PMID: 28318726. doi:10.1016/j.eururo.2017.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。